Kristin Stephens - 08 Jun 2021 Form 3 Insider Report for Syros Pharmaceuticals, Inc. (SYRS)

Role
Chief Development Officer
Signature
/s/ Kristin Stephens
Issuer symbol
SYRS
Transactions as of
08 Jun 2021
Net transactions value
$0
Form type
3
Filing time
10 Jun 2021, 17:23:48 UTC
Next filing
17 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding SYRS Common Stock 45,000 08 Jun 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding SYRS Stock Option (right to buy) 08 Jun 2021 Common Stock 20,000 $6.94 Direct F2
holding SYRS Stock Option (right to buy) 08 Jun 2021 Common Stock 6,666 $8.51 Direct F2
holding SYRS Stock Option (right to buy) 08 Jun 2021 Common Stock 6,666 $11.66 Direct F2
holding SYRS Stock Option (right to buy) 08 Jun 2021 Common Stock 12,750 $12.59 Direct F2
holding SYRS Stock Option (right to buy) 08 Jun 2021 Common Stock 38,200 $10.90 Direct F2
holding SYRS Stock Option (right to buy) 08 Jun 2021 Common Stock 30,000 $10.09 Direct F3
holding SYRS Stock Option (right to buy) 08 Jun 2021 Common Stock 7,200 $12.29 Direct F4
holding SYRS Stock Option (right to buy) 08 Jun 2021 Common Stock 53,350 $6.71 Direct F5
holding SYRS Stock Option (right to buy) 08 Jun 2021 Common Stock 84,000 $7.54 Direct F6
holding SYRS Stock Option (right to buy) 08 Jun 2021 Common Stock 10,000 $9.17 Direct F7
holding SYRS Stock Option (right to buy) 08 Jun 2021 Common Stock 94,000 $11.41 Direct F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person was granted restricted stock units, with each unit representing the right to receive one share of the issuer's common stock. These restricted stock units will vest in full on March 31, 2022.
F2 This option is fully vested.
F3 Option vested as to 25% of the shares on February 28, 2019 with the remaining shares vesting in equal monthly installments thereafter through February 28, 2022.
F4 Option vested as to 25% of the shares on August 31, 2019 with the remaining shares vesting in equal monthly installments thereafter through August 31, 2022.
F5 Option vested as to 25% of the shares on February 29, 2020 with the remaining shares vesting in equal monthly installments thereafter through February 28, 2023.
F6 Option vested as to 25% of the shares on February 28, 2021 with the remaining shares vesting in equal monthly installments thereafter through February 28, 2024.
F7 Option vests as to 25% of the shares on June 11, 2021 with the remaining shares vesting in equal monthly installments thereafter through June 11, 2024.
F8 Option vests as to 25% of the shares on February 28, 2022 with the remaining shares vesting in equal monthly installments thereafter through February 28, 2025.

Remarks:

Exhibit 24: Power of Attorney